Travere Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023
For the year, the company expects net product sales from continuing operations to be approximately $128 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.34 USD | +0.63% | -3.21% | -29.48% |
1st Jan change | Capi. | |
---|---|---|
-29.48% | 483M | |
+5.66% | 111B | |
+11.23% | 105B | |
-0.38% | 21.93B | |
-12.15% | 22.34B | |
-7.66% | 18.59B | |
-36.52% | 18.12B | |
-10.09% | 16.96B | |
+3.33% | 13.7B | |
+36.58% | 12.45B |